These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 36319536)

  • 21. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying Patients for Nonstatin Therapy.
    Robinson JG; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
    Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.
    Koenig W; Lorenz ES; Beier L; Gouni-Berthold I
    Clin Res Cardiol; 2024 Jun; 113(6):812-821. PubMed ID: 37603070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates on Non-Statin LDL-Lowering Therapy.
    Abdulla A; Shalaby M; Kumfa P; Raja M; Allencherril J; Sharifeh TA
    Curr Cardiol Rep; 2024 Apr; 26(4):221-231. PubMed ID: 38436784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
    Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
    Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
    D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
    Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
    Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID).
    Shah NN; Ghazi L; Yamamoto Y; Martin M; Simonov M; Riello RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
    Am Heart J; 2022 Nov; 253():76-85. PubMed ID: 35841944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?].
    Katzmann JL; Laufs U
    Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
    Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D
    Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.